A pioneering uterine cancer trial could cut time for women to diagnose the disease and reduce the need for more invasive diagnostic procedures.
Research published in the Journal of Clinical Oncology shows that low-cost PCR tests that take samples from the cervix or vagina can successfully detect uterine cancer.
Currently in the UK, women have common uterine symptoms cancer – such as abnormal vaginal bleeding – a transvaginal ultrasound is recommended.
If doctors are concerned about the thickness of a woman’s uterine lining, they may need to do invasive tests such as hysteroscopy or a biopsy, which some describe as painful.
Researchers and campaigners hope the new trial will reduce the need for more invasive diagnostic procedures.
Professor Martin Widschwendter, from the European Institute of Translational Cancer Prevention and Control at the University of Innsbruck and UCL’s Department of Women’s Cancer in the UK, said: “It was important to us that this study solved the problem. address all issues related to current detection methods for uterine cancer.
“Most importantly, using our test, fewer women with abnormal bleeding will have to undergo invasive diagnostic procedures.”
Athena Lamnisos, executive director of charity The Eve Appeal, said: “This research shows real promise in reducing the time to diagnosis, making a specific diagnosis available to everyone and reducing the need for intervention. painful and invasive interventions.
“It really helps to detect cancer early one stage closer.”
Early results show that the test works for all groups – regardless of age, ethnicity, pre- or post-menopausal and the stage, grade and type of cancer they have.
The researchers used 1,288 cervical screening samples from women with and without uterine cancer collected by a large group of investigators across the UK and Europe.
The trial successfully identified all eight types of uterine cancer in a cohort of 63 women presenting with postmenopausal bleeding and only a handful of women without cancer testing positive, making This test is more specific than transvaginal ultrasound which has a specificity of 89%.
The new trial was developed by Professor Widschwendter and his team at the Universities of Innsbruck and UCL and is funded by the EU’s Horizon 2020 program and the European Research Council, The Eve Appeal and the Tirol region’s regional government. Shirt.